Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
OPTUS Pharmaceutical Co., Ltd. Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.	South Korea	131030
Opus Genetics, Inc. Developing gene therapies for inherited retinal diseases and other blinding conditions.	United States of America	IRD
ORAGENICS INC Biotech developing intranasal drugs for concussion and other brain disorders.	United States of America	OGEN
Oramed Pharmaceuticals Inc. Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.	Israel	ORMP
ORASURE TECHNOLOGIES INC Develops and distributes point-of-care diagnostic tests and sample collection devices.	United States of America	OSUR
Orexo Develops pharmaceuticals & digital health for opioid use disorder in the US market.	Sweden	ORX
ORGANIGRAM GLOBAL INC. Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.	United States of America	OGI
Organon & Co. A global healthcare company focused on women's health, biosimilars, and established brands worldwide.	United States of America	OGN
Oric Pharmaceuticals, Inc. Developing therapies to overcome resistance in lung and prostate cancer.	United States of America	ORIC
Orion Oyj Develops and manufactures human/vet pharma, APIs, and generics for global markets.	Finland	ORNAV